Botulinum Toxin for Scalp Conditions: A Systematic Review.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
2
11
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
ppublish
Résumé
Many reports have described the use of botulinum toxin (BTX) in the treatment of scalp conditions, but no studies have synthesized these collective findings. We conducted a systematic review to summarize the scalp conditions for which treatment with BTX has been described. We searched PubMed/MEDLINE and Scopus for articles in English published before November 1, 2022, using the keywords "hair" or "scalp" and BTX-related search terms. Articles that described patients who received injections of BTX for the management of scalp conditions were included. Twenty-four original articles (12 case reports, 9 clinical trials, and 3 case series) were identified that described 309 patients with a scalp condition treated with BTX. Androgenetic alopecia, craniofacial hyperhidrosis, and scalp hyperseborrhea had the most robust data supporting the clinical efficacy of BTX. The current quality of evidence is highly variable and, for many conditions, limited to small observational studies. Botulinum toxin may be a promising therapeutic option for patients with various scalp conditions, but future studies are needed to better understand its efficacy and safety.
Sections du résumé
BACKGROUND
Many reports have described the use of botulinum toxin (BTX) in the treatment of scalp conditions, but no studies have synthesized these collective findings.
OBJECTIVE
We conducted a systematic review to summarize the scalp conditions for which treatment with BTX has been described.
METHODS
We searched PubMed/MEDLINE and Scopus for articles in English published before November 1, 2022, using the keywords "hair" or "scalp" and BTX-related search terms. Articles that described patients who received injections of BTX for the management of scalp conditions were included.
RESULTS
Twenty-four original articles (12 case reports, 9 clinical trials, and 3 case series) were identified that described 309 patients with a scalp condition treated with BTX. Androgenetic alopecia, craniofacial hyperhidrosis, and scalp hyperseborrhea had the most robust data supporting the clinical efficacy of BTX.
CONCLUSION
The current quality of evidence is highly variable and, for many conditions, limited to small observational studies. Botulinum toxin may be a promising therapeutic option for patients with various scalp conditions, but future studies are needed to better understand its efficacy and safety.
Identifiants
pubmed: 37556465
doi: 10.1097/DSS.0000000000003895
pii: 00042728-990000000-00466
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Neuromuscular Agents
0
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1023-1026Informations de copyright
Copyright © 2023 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
AokiGuyer KRB. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8:21–9.
Zhou Y, Yu S, Zhao J, Feng X, et al. Effectiveness and safety of botulinum toxin type A in the treatment of androgenetic alopecia. Biomed Res Int 2020;2020:1–7.
Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg 2010;126:246e–8e.
Tian K, Gao S, Jia Z, Xu W, et al. A study of combination unilateral subcutaneous botulinum toxin a treatment for androgenetic alopecia. J Cosmet Dermatol 2022;21:5584–90.
Neema S, Singh S, Vasudevan B. A pilot study to evaluate effectiveness of botulinum toxin in treatment of androgenetic alopecia in males. J Cutan Aesthet Surg 2017;10:163–7.
Nassar A, Abdel-Aleem H, SamirKhattab MFM. Efficacy of botulinum toxin A injection in the treatment of androgenic alopecia: a Comparative Controlled Study. J Cosmet Dermatol 2022;21:4261–8.
Shon U, Kim MH, Lee DY, KimPark SHBC. The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. J Am Acad Dermatol 2020;83:1838–9.
Khattab FM, Rady A, Khashaba SA. Recent modalities in treatment of telogen effluvium: comparative study. Dermatol Ther 2022;35:e15720.
Cho HR, Lew BL, LewSim HWY. Treatment effects of intradermal botulinum toxin type A injection on alopecia areata. Dermatol Surg 2010;36:2175–81.
Lucioni A, Bales GT, Lotan TL, McGehee DS, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008;101:366–70.
Tamura BM, Sortino-RachouCuce AMLC. Letter: folliculitis responds to botulinum toxin: is it possible? Dermatol Surg 2007;33:1398–400.
Bedrin KO, Dougherty C. Cephalgia alopecia. Curr Pain Headache Rep 2020;24:46.
Cutrer FM, Sandroni P, Wendelschafer-Crabb G. Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide-containing cutaneous nerves in scalp. Cephalalgia 2010;30:1000–6.
Cutrer FM, Pittelkow MR. Cephalalgic alopecia areata: a syndrome of neuralgiform head pain and hair loss responsive to botulinum A toxin injection. Cephalalgia 2006;26:747–51.
Irimia P, Palma JA, Idoate MA, Espana A, et al. Cephalalgia alopecia or nummular headache with trophic changes? A new case with prolonged follow-up. J Head Face Pain 2013;53:994–7.
Guo Y, Wei W, Zhang A, Tao C, et al. The combination of platelet-rich plasma with botulinum toxin A in the treatment of hyaluronic acid embolic cutaneous necrosis and alopecia. Dermatol Ther 2022;35:e15442.
Asz-Sigall D, Inigo-Gomez K, Ortega-Springall MF, Vega-Memije ME, et al. Alopecia secondary to hyaluronic acid embolization: trichoscopic findings. Skin Appendage Disord 2019;5:396–400.
Karlqvist M, Rosell K, Rystedt A, Hymnelius K, Swartling C. Botulinum toxin B in the treatment of craniofacial hyperhidrosis. J Eur Acad Dermatol Venereol 2014;28:1313–7.
Park JH, Kim R, Na SH, Kwon SY. Effect of botulinum toxin in stellate ganglion for craniofacial hyperhidrosis: a case report. J Int Med Res 2021;49:030006052110042.
Alsharqi A, Wilson NJ. Craniofacial hyperhidrosis in post-menopausal women. Australas J Dermatol 2012;53:158–9.
Komericki P, Ardjomand N. Hyperhidrosis of face and scalp: repeated successful treatment with botulinum toxin type A. Indian J Dermatol Venereol Leprol 2012;78:201–2.
Eustace K, Wilson NJ. Postmenopausal craniofacial hyperhidrosis. Clin Exp Dermatol 2018;43:180–2.
Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 2002;249:1729–32.
Hannan E, Hechler B, Powers D. A unique case of primary focal hyperhidrosis and treatment. Oral Maxillofac Surg Cases 2022;8:100264.
Li Y, Chen X, Luo X, Li L, Lin Y. Intradermal botulinum toxin A injection for scalp sebum secretion regulation: a multicenter, randomized, double-blinded, placebo-controlled, prospective study in Chinese subjects. Aesthet Surg J 2022;43:NP38–48.
Rimoin J, Arbiser J. Improvement of "en coup de Sabre" morphea and associated headaches with botulinum toxin injections. Dermatol Surg 2016;42:1216–9.
Borodic GE, Caruso P, Acquadro M, Chick S. Parry-Romberg syndrome vasculopathy and its treatment with botulinum toxin. Ophthalmic Plast Reconstr Surg 2014;30:e22–5.
Lin M, Phan K. Botulinum toxin for scalp dysesthesia. J Cutan Aesthet Surg 2022;15:95–6.
Sifaki MK, Krueger-Krasagakis S, Koutsopoulos A, Evangelou GI, Tosca AD. Botulinum toxin type A--treatment of a patient with multiple cutaneous piloleiomyomas. Dermatology 2009;218:44–7.